Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
helped people with obesity lose, on average, around 15% of their weight . The results far exceeded what prior studies of other treatments had suggested was possible pharmaceutically, sparking a rush to research that has quickly reshaped the obesity drug field. Demand for semaglutide, now sold in nine countries by Novo as Wegovy, has surged to such heights the company can't keep up. Physicians see Wegovy and other drugs like it as powerful treatments for obesity as well as its many related health consequences. Analysts forecast annual sales of this new class of medicines to surpass $100 billion by early next decade. Drugmakers are investing billions of dollars in an attempt to get a piece of that market, as would-be competitors test new ways to regulate metabolism and spur weight loss. Some 120 drugs are now in clinical development for obesity, according to a recent report from Iqvia , from Wegovy mimics to psilocybin and coated glucose beads. More than one-third work by stimulat
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Succession drama grips Gucci as sales fail to make the cut [Yahoo! Finance]Yahoo! Finance
- Temedica Expands Its Advisory Board With Former Gematik CEO Markus Leyck Dieken [Yahoo! Finance]Yahoo! Finance
- Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data [Yahoo! Finance]Yahoo! Finance
- Roche says weight loss drug shows promising results in early trial [CNBC]CNBC
- India's Biocon posts Q4 profit fall as higher raw material costs bite [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/15/24 - Form 6-K
- 5/13/24 - Form 6-K
- 5/13/24 - Form 6-K
- NVO's page on the SEC website